ADSL and cancer: Since ADSL is a known oncogenic driver in several cancers and a potential predictive biomarker for response to the purine antimetabolite, 6-mercaptopurine in preclinical models [64], a more in-depth analysis of ADSL, especially in B2 and B3 thymomas appears warranted under a therapeutic perspective.